Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715395 | 0.88 | — | — | |
| SCHEMBL2913439 | 0.82 | SLC6A1 (0.45) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2918078 | 0.80 | KDM4E (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10702729 | 0.79 | SLC6A1 (0.32) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2910857 | 0.79 | GLI1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2917294 | 0.79 | CHRNB2 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL8657863 | 0.74 | LMNA (0.35) | LMNA | |
| SCHEMBL2646452 | 0.72 | — | — | |
| SCHEMBL863279 | 0.70 | — | — | |
| SCHEMBL2915925 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
| EP-2142189-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | Allergan, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121665-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2005107706-A2 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS | ALLERGAN, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | SLC6A1 4723/4885SLC6A11 4670/4885TSHR 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.